Invalid Symbol

Stock Research for IMMY

IMMY
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

IMMY Stock Chart & Research Data

The IMMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IMMY Due diligence Resources & Stock Charts

The IMMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IMMY Detailed Price Forecast - CNN Money CNN View IMMY Detailed Summary - Google Finance
Yahoo View IMMY Detailed Summary - Yahoo! Finance Zacks View IMMY Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View IMMY Trends & Analysis - Trade-Ideas Barrons View IMMY Major Holders - Barrons
NASDAQ View IMMY Call Transcripts - NASDAQ Seeking View IMMY Breaking News & Analysis - Seeking Alpha
Spotlight View IMMY Annual Report - CompanySpotlight.com OTC Report View IMMY OTC Short Report - OTCShortReport.com
TradeKing View IMMY Fundamentals - TradeKing Charts View IMMY SEC Filings - Bar Chart
WSJ View Historical Prices for IMMY - The WSJ Morningstar View Performance/Total Return for IMMY - Morningstar
MarketWatch View the Analyst Estimates for IMMY - MarketWatch CNBC View the Earnings History for IMMY - CNBC
StockMarketWatch View the IMMY Earnings - StockMarketWatch MacroAxis View IMMY Buy or Sell Recommendations - MacroAxis
Bullish View the IMMY Bullish Patterns - American Bulls Short Pains View IMMY Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View IMMY Stock Mentions - StockTwits PennyStocks View IMMY Stock Mentions - PennyStockTweets
Twitter View IMMY Stock Mentions - Twitter Invest Hub View IMMY Investment Forum News - Investor Hub
Yahoo View IMMY Stock Mentions - Yahoo! Message Board Seeking Alpha View IMMY Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for IMMY - SECform4.com Insider Cow View Insider Transactions for IMMY - Insider Cow
CNBC View IMMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IMMY - OTC Markets
Yahoo View Insider Transactions for IMMY - Yahoo! Finance NASDAQ View Institutional Holdings for IMMY - NASDAQ


Stock Charts

FinViz View IMMY Stock Insight & Charts - FinViz.com StockCharts View IMMY Investment Charts - StockCharts.com
BarChart View IMMY Stock Overview & Charts - BarChart Trading View View IMMY User Generated Charts - Trading View


Latest Financial News for IMMY

Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
Posted on Thursday February 15, 2018

SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday, March 8, 2018.  The company will host a conference call at 4:30 p.m. EST/1:30 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until April 8, 2018.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 25720.  The webcast replay will be available until June 8, 2018.


Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals
Posted on Wednesday January 31, 2018

NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones ...


Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
Posted on Tuesday January 30, 2018

I am going to take a deep dive into Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...


Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
Posted on Tuesday January 30, 2018

SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt® and Cosopt® PF, were added to the FDA Drug Shortage List.


Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report ...
PR Newswire (press release) - Feb 15, 2018
Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician ...

Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug ...
PR Newswire (press release) - Jan 30, 2018
Imprimis will not dispense these formulations with preservatives such as benzalkonium chloride (BAK) which is typically used in many topical glaucoma drugs.

Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B ...
PR Newswire (press release) - Jan 24, 2018
SAN DIEGO, Jan. 24, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered ...

Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q2 2017 Results - Earnings ...
Seeking Alpha - Aug 11, 2017
Good afternoon and welcome to the conference call covering Imprimis Pharmaceuticals financial results and business update for the second quarter 2017.

Enter a stock symbol to view the stock details.